Burden of atopic dermatitis in Asia

Tsai, Tsen‐Fang; Rajagopalan, Murlidhar; Chu, Chia-Yu; Encarnacion, Lonabel; Gerber, Robert A.; Santos-Estrella, Paul; Llamado, Lyndon; Tallman, Anna M.

doi:10.1111/1346-8138.15048

Cited by 70 publications

(75 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the latter study, for German patients costs were higher for AD than for psoriasis and rheumatoid arthritis (€941, €224 and €628, respectively) 15 . Similar cost estimates have been published for AD in Singapore, 16 the Asia Pacific region, Thailand, South Korea and Vietnam 17 . Understandably, cost increases with disease severity 12,14,16 …”

supporting

confidence: 62%

The global burden of atopic dermatitis: lessons from the Global Burden of Disease Study 1990–2017*

et al. 2020

View full text Add to dashboard Cite

Summary Background The Global Burden of Disease (GBD) Study provides an annually updated resource to study disease‐related morbidity and mortality worldwide. Objectives Here we present the burden estimates for atopic dermatitis (AD), including data from inception of the GBD project in 1990 until 2017. Methods Data on the burden of AD were obtained from the GBD Study. Results Atopic dermatitis (AD) ranks 15th among all nonfatal diseases and has the highest disease burden among skin diseases as measured by disability‐adjusted life‐years (DALYs). Overall, the global DALY rate for AD in 1990 was 121 [95% uncertainty interval (UI) 65·4–201] and remained similar in 2017 at 123 (95% UI 66·8–205). The three countries with the highest DALY rates of AD were Sweden (327, 95% UI 178–547), the UK (284, 95% UI 155–478) and Iceland (277, 95% UI 149–465), whereas Uzbekistan (85·1, 95% UI 45·2–144), Armenia (85·1, 95% UI 45·8–143) and Tajikistan (85·1, 95% UI 46·1–143) ranked lowest. Conclusions The global prevalence rate of AD has remained stable from 1990 to 2017. However, the distribution of AD by age groups shows a bimodal curve with the highest peak in early childhood, decreasing in prevalence among young adults, and a second peak in middle‐aged and older populations. We also found a moderate positive correlation between a country’s gross domestic product and disease burden. GBD data confirm the substantial worldwide burden of AD, which has remained stable since 1990 but shows significant geographical variation. Lifestyle factors, partially linked to affluence, are likely important disease drivers. However, the GBD methodology needs to be developed further to incorporate environmental risk factors, such as ultraviolet exposure, to understand better the geographical and age‐related variations in disease burden.

show abstract

supporting

confidence: 62%

The global burden of atopic dermatitis: lessons from the Global Burden of Disease Study 1990–2017*

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Tsai et al [117] state in their 2019 review data that available data regarding the impact of atopic dermatitis on QoL in Asia are limited. They conclude that atopic dermatitis is associated with a significant burden within Asian countries with a significant impact on QoL.…”

Section: Quality Of Lifementioning

confidence: 99%

Burden and socioeconomics of asthma, allergic rhinitis, atopic dermatitis and food allergy

Dierick

Molen

Blok

et al. 2020

Expert Review of Pharmacoeconomics & Outcomes Research

201

157

View full text Add to dashboard Cite

Introduction: Asthma, allergic rhinitis, atopic dermatitis, and food allergy affect approximately 20% of the global population. Few studies describe the burden of the totality of these diseases and only a handful studies provide a comprehensive overview of the socioeconomic impact of these diseases. Areas covered: For this narrative review, we searched Pubmed using selected keywords and inspected relevant references using a snowballing process. We provide an overview of the socioeconomic burden of allergic diseases (in particular, asthma, allergic rhinitis, atopic dermatitis, and food allergy). The focus of this review is on their epidemiology (incidence, prevalence), burden (disability-adjusted life years, quality of life), and direct and indirect costs (absenteeism and presenteeism). We have put special emphasis on differences between countries. Expert commentary: Both the prevalence and the burden of allergic diseases are considerable with prevalence varying between 1% and 20%. We identified a plethora of studies on asthma, but studies were generally difficult to compare due to the heterogeneity in measures used. There were only few studies on the burden of food allergy; therefore, more studies on this allergy are required. For future studies, we recommend standardizing epidemiologic, socioeconomic impact, and quality of life measures of allergic diseases.

show abstract

“…The prevalence of AD has been increasing in Asia in recent years. This has been attributed to the Westernization of lifestyle and diet in Asia [29]. On the other hand, soy protein intake is known to be higher in Asians than in Europeans and Americans due to Asian dietary culture.…”

Section: Discussionmentioning

confidence: 99%

The Connection between Urinary Equol Levels and the Prevalence of Atopic Dermatitis

Chiba

Nagai

Kohda

et al. 2020

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Background: Soy isoflavones and their metabolites such as equol have been associated with a reduced risk of hormone-sensitive tumors and metabolic syndromes. However, individual soy isoflavones and equol levels in atopic dermatitis remain uninvestigated. Objective: The aim of this study is to compare the levels of urinary daidzein, genistein, and equol between atopic dermatitis patients and normal subjects and to examine the correlation between equol concentration and the severity of clinical symptoms. Methods: A cross-sectional study was conducted at Akita University Hospital and Aso Iizuka Hospital in Japan. Fifty patients with confirmed atopic dermatitis diagnosis and 67 healthy controls were recruited. Daidzein, genistein, and equol in urine were measured by using a high-performance liquid chromatography-mass spectrometry system. Results: Urinary equol levels were significantly lower in the atopic dermatitis patients than in the healthy controls (p = 0.002). The difference was particularly noticeable in young people (6–19 years, p < 0.001). No correlations were found between urinary equol levels and the severity of clinical symptoms and laboratory data in the atopic dermatitis patients. Conclusion: Equol levels in childhood might be involved in the development of atopic dermatitis.

show abstract

Burden of atopic dermatitis in Asia

Cited by 70 publications

References 74 publications

The global burden of atopic dermatitis: lessons from the Global Burden of Disease Study 1990–2017*

The global burden of atopic dermatitis: lessons from the Global Burden of Disease Study 1990–2017*

Burden and socioeconomics of asthma, allergic rhinitis, atopic dermatitis and food allergy

The Connection between Urinary Equol Levels and the Prevalence of Atopic Dermatitis

Contact Info

Product

Resources

About